Treatment of COVID-19 Patients during Second Wave in a Tertiary Care Center of Nepal
Keywords:COVID-19, cost, drugs
The second wave of the COVID-19 pandemic was confirmed in Nepal in April 2021. It was caused by genetic variants of SARS-CoV2. The objective of the study was to find out severity of patients, their treatment and approximate drug cost for the treatment of COVID-19 in the second wave.
In this retrospective, cross-sectional study, data of all patients who tested positive and were admitted in KIST Medical College and Teaching Hospital between April 2021 – July 2021 was collected for the study. A total of 215 patients were included.
Among the cases admitted, 190 (88.4%) patients were symptomatic. ICU/HDU admission was done in 113 (52.5%) cases, among which 33 (29.2%) patients received ventilator support. The patients treated in isolation unit were 102 (47.4%). Among the patients admitted, 23 (10.7%) were vaccinated. Severe cases were 80 (37%), moderate cases were 71 (33%) and mild cases were 49 (23%). Antibiotics were used in 190 (88.4%) cases. More than one antibiotics were used in 141 (65.6%) cases. Antifungals were used in 39 (18.1%) cases. Other drugs like corticosteroids were used in 185 (86%), proton-pump inhibitors in 179 (84.3%), antihistaminics in 169 (78.4%) and anticoagulants in 165 (76.7%), Vitamin C in 153 (71.2%), Vitamin D in 152 (70.7%) and zinc in 140 (65.1%) cases. The number of patients discharged after recovery was 151 (70.2%) and 41 (19.5%) patients died. The average drug cost was NPR. 3,246 in mild, 27,645 in moderate and 76,420 in severe cases.
Majority of patients were treated in ICU/HDU. Most commonly used drugs were antibiotics, corticosteroids and anticoagulants. Mortality was high in the second wave.
How to Cite
Copyright (c) 2022 Journal of Institute of Medicine Nepal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.